Clinical trials
Primary Myelofibrosis trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 13 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Active, not recruiting | 14 |
| Recruiting | 14 |
| Terminated | 7 |
| Unknown status | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Incyte Corporation | 7 |
| AbbVie | 5 |
| Celgene | 4 |
| Kartos Therapeutics, Inc. | 4 |
| FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 3 |
| Karyopharm Therapeutics Inc | 3 |
| Sierra Oncology LLC - a GSK company | 3 |
| Geron Corporation | 2 |
| GlaxoSmithKline | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Myelofibrosis | 59 |
| Myeloproliferative Disorders | 16 |
| Polycythemia Vera | 8 |
| Anemia | 7 |
| Thrombocythemia, Essential | 7 |
| Neoplasms | 6 |
| Hematologic Diseases | 4 |
| Bone Marrow Diseases | 3 |
| Recurrence | 3 |
| Thrombocytosis | 3 |
Trials
Showing 26 to 50 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.